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ABSTRACT
ObjeCtive
To examine changes in colorectal cancer mortality in 
34 European countries between 1970 and 2011.
Design
Retrospective trend analysis.
Data sOurCe
World Health Organization mortality database.
POPulatiOn
Deaths from colorectal cancer between 1970 and 2011. 
Profound changes in screening and treatment 
efficiency took place after 1988; therefore, particular 
attention was paid to the evolution of colorectal cancer 
mortality in the subsequent period.
Main OutCOMes Measures
Time trends in rates of colorectal cancer mortality, 
using joinpoint regression analysis. Rates were age 
adjusted using the standard European population.
results
From 1989 to 2011, colorectal cancer mortality 
increased by a median of 6.0% for men and decreased 
by a median of 14.7% for women in the 34 European 
countries. Reductions in colorectal cancer mortality of 
more than 25% in men and 30% in women occurred in 
Austria, Switzerland, Germany, the United Kingdom, 
Belgium, the Czech Republic, Luxembourg, and 
Ireland. By contrast, mortality rates fell by less than 
17% in the Netherlands and Sweden for both sexes. 
Over the same period, smaller or no declines occurred 
in most central European countries. Substantial 
mortality increases occurred in Croatia, the former 
Yugoslav republic of Macedonia, and Romania for both 
sexes and in most eastern European countries for men. 
In countries with decreasing mortality, reductions were 
more important for women of all ages and men younger 
than 65 years. In the 27 European Union member 
states, colorectal cancer mortality fell by 13.0% in men 
and 27.0% in women, compared with corresponding 
reductions of 39.8% and 38.8% in the United States. 
COnClusiOn
Over the past 40 years, there has been considerable 
disparity in the level of colorectal cancer mortality 
between European countries, as well as between men 
and women and age categories. Countries with the 
largest reductions in colorectal cancer mortality are 
characterised by better accessibility to screening 
services, especially endoscopic screening, and 
specialised care.
Introduction
Colorectal cancer is the second most commonly diag-
nosed cancer in the world and has poor prognosis when 
metastasised to lymph nodes or distant organs. After 
lung cancer, it is the most common cause of cancer 
death in Europe. In 2012, it was estimated that 241 600 
European men were diagnosed with colorectal cancer, 
and that 113 200 men died from the disease. For Euro-
pean women, 205 200 cases of colorectal cancer and 
101 500 related deaths were recorded that year.1 
Over the past two decades in Europe, early detection 
of colorectal cancer has increased through screening 
and easier access to endoscopic removal of adeno-
matous polyps (the most common precursor lesion).2 
At the same time, new treatments have been developed 
and their availability improved. Several reports have 
shown that colorectal cancer mortality has been 
steadily decreasing for at least two decades in several 
high income countries such as the United States3 4  and 
Japan.5  A similar pattern has also been observed in 
Europe, with declining mortality trends since the early 
1980s and 1990s for men and women, respectively.6 7 
These studies also highlighted important disparities 
between countries, particularly between northwest 
Europe (where the earliest and largest declines were 
observed) and the rest of Europe. 
In this study, we analysed data on colorectal cancer 
mortality from 34 European countries between 1970 
and 2011 by age and sex. Following the lead of previous 
articles that focused on major European countries,6 our 
aim was to expand on their findings and provide up to 
date, long term temporal trends of colorectal cancer 
mortality for all European countries. We also examined 
recent mortality trends in relation to levels in 1989-91, 
before the advent of more efficient patient management 
WhAT IS AlReAdy knoWn on ThIS TopIC
Colorectal cancer is a major public health issue in most western countries
Since 1989, many European countries have undergone changes in the prevalence of 
risk factors for colorectal cancer (such as obesity and alcohol intake), participation 
in screening programmes, and access to specialised care and effective treatments
WhAT ThIS STudy AddS
Colorectal cancer mortality is falling in an increasing number of European countries, 
despite persistent differences between men and women and between specific 
regions in Europe
In 1989-2011, the largest reductions in colorectal cancer mortality were observed in 
countries with increased screening participation and improved access to 
specialised care; in most central European countries, mortality has been stable or 
slightly decreasing since the early 2000s, but is still increasing in most eastern 
European countries
Strategies already in place in several European countries could be used as models 
to design and implement effective health policies to prevent death from colorectal 
cancer
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and expansion of screening activities. For the sake of 
comparison, we performed a similar analysis of corre-
sponding mortality data in the 27 European Union 
member states (as one group) and the USA.
Methods
Mortality data
The number of deaths from colorectal cancer was 
obtained from the World Health Organization mortality 
database for 34 European countries and the USA for the 
period 1970-2011.8  The WHO mortality database pro-
vides annual data on mortality statistics by age, sex, and 
cause of death as obtained by national registration sys-
tems. A detailed assessment of data completeness and 
quality has been conducted by Mathers and colleagues.9 
Between 1970 and 2011, data on cause of death was 
classified by use of three versions of the international 
classification of diseases (ICD, 8th to 10th revisions). We 
defined colorectal cancer mortality as any death with 
an ICD-8 code of A048-A049, ICD-9 code of B093-B094, 
or ICD-10 code of C18-C21. We also included any death 
with an ICD code for cancers of the anus or anal canal 
because it was unclear from the database how some 
countries used the different ICD coding schemes to clas-
sify cancers into the various subsites of colorectal cancer: 
“colon,” “recto-sigmoid junction,” “rectum,” “anus,” 
and “anal canal.” 
For the majority of countries, data were available for 
most or all of the period of interest. Cyprus was not 
included because data were only available for four 
years (1999, 2000, 2004, 2006). For Switzerland, data 
were available only until 2010. Furthermore, a change 
in coding practice in 1994 resulted in an over-reporting 
of cancer mortality before 1994. We therefore applied a 
correction factor of 0.94 to all mortality rates before 
1995, as recommended by Lutz and colleagues.10 For 
most central and eastern European countries, data were 
available since the early to mid-1980s until 2009-10—
apart from Bulgaria, for which data were available for 
the entire period. For Slovakia and the former Yugoslav 
republic of Macedonia, data were available from 1991 
and 1992, respectively, until 2010. Web table 1 lists the 
specific years with missing data for each country. 
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination.
statistical analyses
We used the direct method and age specific population 
estimates from the WHO mortality database8  to compute 
age adjusted mortality rates of colorectal cancer, accord-
ing to the age distribution of the standard European 
population.11 Joinpoint regression analysis was 
 performed over the whole period to identify years when 
significant changes in mortality rates occurred. We then 
calculated annual percent changes (relative change) for 
each country, by fitting a regression line to the natural 
logarithm of the rates on the period 1989-2011 and over 
the last five years of available data (2007-2011). Because 
of missing data, regression was fitted over the periods 
1992-2010 for Slovakia and 1991-2010 for Macedonia. 
Based on the underlying joinpoint model, overall per-
cent changes were then derived for the period 1989-2011. 
We conducted these analyses separately for men and 
women of all ages, and for specific age categories (<65, 
65-79, and ≥80 years). We used these age groups for 
three main reasons. Firstly, 65 years is the maximal 
legal retirement age in most European countries, which 
implies potential changes in lifestyle factors, screening, 
and access to treatment. Secondly, most colorectal can-
cers are diagnosed in people aged 65-79 years. And 
thirdly, patients with the disease aged 80 years and 
older require specific treatment modalities and often 
have more adverse events (including death) related to 
treatment than younger populations.12 13  We undertook 
all joinpoint regression analysis using the publicly 
available joinpoint software from the surveillance 
research programme of the US National Cancer Insti-
tute.14 Web table 2 lists the modelling parameters. 
Results
Figures 1  and 2 provide an overview of the evolution of 
colorectal cancer mortality by sex and for all ages 
between 1970 and 2011 (or the last year of available 
data). Web figures 1-3 show the mortality trends by age 
(<65, 65-79, and ≥80 years). Important differences in col-
orectal cancer mortality exist between countries. Large 
declines in mortality occurred in northern and western 
European countries. We observed increasing mortality 
rates mostly in countries in southern, central, and east-
ern Europe—apart from the Czech Republic, which had 
one of the largest declines in mortality for both sexes.
We were most interested in the recent trends in col-
orectal cancer mortality (1989-2011), because the most 
profound changes in screening and treatment efficiency 
took place after 1988. Figure 3 summarises the evolu-
tion of mortality in 1989-2011 and highlights the diverse 
results across Europe. Large differences can be observed 
between men and women and between countries, 
including those with comparable high level economies. 
For example, between 1989 and 2011 in the Nether-
lands, rates of colorectal cancer mortality fell by only 
11.6% and 16.7% for men and women, respectively. But 
in the United Kingdom, Germany, and Austria, the cor-
responding rates fell by more than 30% for both sexes—
despite the four countries having similar rates as the 
Netherlands in 1989-91. In the 27 European Union mem-
ber states, mortality decreased by 13% for men and 27% 
for women. 
The largest reductions in colorectal cancer mortal-
ity for both sexes occurred in western and northern 
Europe. Important decreases in mortality also took 
place in southern European countries and some 
 eastern European countries for women. In central, 
eastern, and southern European countries, mortality 
rose until later years. In 1989-91, the highest mortality 
rates were in Hungary, Slovakia, and the Czech 
Republic. In other countries, mortality trends stabi-
lised or showed first signs of decline after 2000. 
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Fig 1 | evolution of colorectal cancer mortality in europe between 1970 and 2011, by sex (austria to lithuania) 
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Fig 2 | evolution of colorectal cancer mortality in europe between 1970 and 2011, by sex (luxembourg to usa). eu-27=27 european union member states
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 Sustained mortality increases in both sexes were 
observed in Latvia,  Macedonia, Romania, and the 
Russian Federation (figs 1 and 2).
Table 1 shows the changes in colorectal cancer mor-
tality for men. In 1989-91, mortality ranged from 10.7 
deaths per 100 000 people in Greece to 53.0 deaths per 
100 000 people in the Czech Republic. In 1989-2011, 
mortality trends ranged from a reduction of 44.1% in 
Austria to an increase of 102.0% in Romania. Mortality 
decreases of 10% or more were observed in 15 countries, 
while increases of 10% or more were also observed in 15 
countries. Average mortality for European men 
 therefore remained constant at 27.3 deaths per 100 000 
people between 1989-91 and 2009-11. In the later period, 
however, the mortality difference between the two 
countries with the highest and lowest mortality rates 
was reduced from fivefold to threefold.
Table 2 shows the changes in colorectal cancer mor-
tality for women. In 1989-91, mortality rates ranged 
from 8.9 deaths per 100 000 people in Greece to 28.2 
per 100 000 people in Hungary. In 1989-2011, mortal-
ity trends ranged from a reduction of 50.4% in Austria 
to an increase of 56.1% in Macedonia. Mortality 
decreases of more than 10% were observed in 20 
countries, while increases of 10% or more were 
observed in nine countries. The average mortality rate 
for European women decreased from 18.1 deaths per 
100 000 people in 1989-91 to 15.3 deaths per 100 000 
people in 2009-11. Although mortality rates in 1989-91 
were on average about one half lower for women than 
for men, subsequent decreases in mortality in Europe 
were more pronounced for women. In most countries, 
reductions in mortality usually started earlier for 
women than for men; in countries with mortality 
increases, rates for men were substantially higher 
than for women.
For all of Europe combined, the reductions in colorec-
tal cancer mortality were more marked for men under 
age 65 years, whereas reductions for women younger 
than 80 years were comparable. However, there were 
major differences in mortality between regions. In most 
western and northern Europe, decreases were generally 
more pronounced in people younger than 65 years 
(tables 1 and 2). But some heterogeneity existed among 
these countries, because decreases tended to be similar 
or more important in older people in Germany, Switzer-
land, the Netherlands, France, and Finland. In central 
and eastern European countries, people aged 80 years 
or older had substantial increases in mortality 
 compared with their younger counterparts. In the 27 
European Union member states in 2007-11, 6.5% of all 
people who died from colorectal cancer were younger 
than 55 years. In the USA in 1989-2011, mortality fell by 
39.8% for men and 38.8% for women (tables 1 and 2); 
mortality decreases were greatest for those aged 65 years 
or older.
discussion 
Our study documents the considerable diversity of mor-
tality trends in colorectal cancer across European coun-
tries over the past four decades. It shows falling 
mortality trends for men and women in an increasing 
number of countries despite persistent differences 
between the sexes and specific regions in Europe. These 
results confirm and build on past work by Bosetti and 
colleagues6 using four more years of mortality data and 
by providing detailed mortality trends for all European 
countries. 
In most countries with falling rates of colorectal can-
cer mortality, the decrease began between 1970 and up 
to the mid-1990s. There were sustained reductions in 
mortality between 1989 and 2011 for most northern, 
western, and some central European countries. Our 
results suggest that these reductions are likely to con-
tinue and may have been accelerating in the recent 
past. Our findings also confirm the stabilised mortality 
trends observed in most central and eastern European 
countries since the early 2000s, particularly for women 
and people younger than 65 years. Some of these 
 countries, however, continue to have very high rates, 
particularly for men. Changes in mortality over time 
could be due to various factors, including demographic 
characteristics, lifestyle, disease awareness, screening, 
and access to effective treatment. 
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age and sex specific reductions in colorectal cancer 
mortality
Reductions in colorectal cancer mortality began 
 earlier and were usually much larger for women. 
 Conversely, in countries where mortality was on the 
rise, the increases were usually more pronounced for 
men. Several behavioural and physiological factors 
have been identified as potential explanations for this 
difference in the burden of the disease between the 
sexes. For example, use of oestrogenic hormone by 
women has been associated with a reduced risk of col-
orectal cancer.15  Furthermore, men are less likely than 
women to participate in screening.16  Men, on average, 
have less contact than women with the healthcare sys-
tem, are less well informed about health issues, pay 
less attention to symptoms, and are less inclined to 
seek medical advice.17 18  Men have less varied dietary 
habits and higher levels of smoking and alcohol con-
sumption than women, which might also be associ-
ated with their higher rates of mortality from 
colorectal cancer.19
The considerable differences in age specific trends in 
colorectal cancer mortality observed across Europe 
might be related to demographic differences between 
countries. Older age has been associated with a more 
advanced stage at diagnosis and less intensive treat-
ment,20 21  while younger patients with colorectal cancer 
have a better survival, irrespective of their characteris-
tics, stage at diagnosis, and treatment received.22 
lifestyle 
The disparities in colorectal cancer mortality trends 
could be partly due to contrasting prevalence of life-
style risk factors across Europe. For instance, several 
studies have shown that the acute increase in alcohol 
consumption observed since 1989 in countries of the 
former Soviet Union is likely to have contributed to the 
higher incidence and mortality levels of colorectal can-
cer in those countries.23-25  Similarly, the improvement 
in colorectal cancer mortality rates in younger age 
groups of some central and eastern European countries 
could, at least in part, be related to protective lifestyle 
factors, such as a more diversified diet (for example, 
containing lower amounts of fat) and reduced alcohol 
consumption.26  This birth cohort phenomenon is per-
haps more relevant to central European countries, 
where dramatic changes in lifestyle have taken place 
after 1989, potentially leading to decreases in the col-
orectal cancer burden. 26 27
The so-called Mediterranean diet has been associ-
ated with a moderately protective effect against colorec-
tal cancer.28  However, lower adherence to this dietary 
pattern over the past 30 years has been reported in 
 Portugal, Spain, Italy, and Greece,29-32 which might be 
associated with the rising or modestly decreasing rates of 
colorectal cancer mortality observed in these countries.
Several studies have consistently reported associa-
tions between obesity, physical inactivity, and diabetes 
mellitus, and the occurrence and poor prognosis of col-
orectal cancer.33-36  The prevalence of these risk factors 
varies substantially between European countries37 and 
tends to increase in many communities. These increas-
ing prevalences might also explain the higher mortality 
rates observed in some countries and particularly in 
those where populations have limited access to screen-
ing and efficient treatments. 
awareness 
Another potential reason behind the large and early 
reductions in colorectal cancer mortality observed in 
some countries is the level of awareness of colorectal 
cancer among physicians and the public. In our study, 
nationwide decreases in mortality often started in the 
1970s—therefore, at least two decades before the intro-
duction of any screening programme or the diffusion of 
effective treatments seen in the 1990s. These initial 
reductions in mortality have been suggested to be due 
to increasing disease awareness, which spurred 
patients to consult more quickly for bowel symptoms 
and doctors to speed up referrals for bowel examina-
tion.38 
screening 
The publication of randomised trials demonstrating the 
ability of regular faecal occult blood testing (FOBT) to 
reduce the risk of death from colorectal cancer39 40  was 
the starting point of FOBT based screening activities in 
several European countries (such as France and the 
UK). Similarly, sigmoidoscopy trials40  and strong and 
longstanding observational data41 42  supporting the 
effectiveness of colonoscopy screening helped establish 
endoscopy as the primary screening procedure for col-
orectal cancer in the USA as well as in many European 
countries (for example, Austria, the Czech Republic, 
Germany, and Poland).43-45 
However, it was only until the 2000s that European 
governments and health authorities set out to engage in 
more structured screening strategies for colorectal can-
cer—either through the publication of guideline recom-
mendations or organisation of screening programmes. 
Currently, all European countries have a system of 
opportunistic screening (that is, individual initiative or 
following a doctor’s recommendation), organised pro-
grammes, or both.
Precise estimates of the effect of screening on col-
orectal cancer mortality at the population level are rare. 
Edwards and colleagues recently suggested that 53% of 
the reduction in mortality observed in the USA could be 
explained by screening—colonoscopy being the most 
widely used procedure.3  In European countries, where 
many organised screening activities have only just 
begun, there is a shortage of data preventing such an 
analysis to be conducted. Nonetheless, the limited data 
available, particularly for European countries with 
comparable high quality healthcare systems but differ-
ent levels of screening activity, are consistent with the 
idea that countries with the largest reductions in col-
orectal cancer mortality also seem to have the highest 
levels of screening, particularly with endoscopy. For 
example, in the Netherlands,46  the availability of colo-
noscopy services is more limited than in France,47 
Austria,48  and Germany.49 
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Similarly, limited pilot projects for FOBT screening 
have been in place in the Netherlands and in Sweden43 
until 2013. In our analysis, both of these countries 
achieved relatively modest reductions in colorectal can-
cer mortality since 1989. A survey of European men and 
women aged 50 years and older using a standardised 
questionnaires found that in 2004, the proportion of 
people who had at least one FOBT over the past 10 years 
was 61% in Austria, 53% in Germany, 24% in France, 
15% in Sweden, and 4% in the Netherlands.50  For 10 
year endoscopic examination of the large bowel, pro-
portions were 24% in Austria and Germany, 25% in 
France, 12% in Sweden, and 10% in the Netherlands. 
These findings strongly suggest that the effect of screen-
ing on colorectal cancer incidence and mortality 
observed in the USA51 52  is also taking place across Euro-
pean countries, particularly for those with high levels of 
endoscopic screening in the population.3
treatment
New treatments, constant advances in surgical tech-
niques, and therapeutic protocols have also been key in 
the reduction of colorectal cancer mortality.53  There has 
been an increasing recognition that specialised care, 
given by medical centres treating large numbers of 
patients with the same condition, is associated with 
higher survival rates.54 55  Over the past two decades, the 
management of patients colorectal cancer has substan-
tially improved, with the introduction of multidisci-
plinary teams, more accurate staging, novel surgical 
approaches, and more effective chemotherapy and 
radiotherapy regimens.56
Potential limitations
Our results should be interpreted with caution because 
the reliability of death certification can vary between 
countries.57  This means that the quality of WHO mortal-
ity data might vary between countries, which in turn 
might have affected the accuracy of our mortality rates. 
However, colorectal cancer is a major neoplasm, and its 
diagnosis and certification are consistent in most Euro-
pean countries.58 Therefore, it is unlikely that errors in 
diagnostic or certification could have significantly 
affected our findings. 
Another potential limitation is that for countries 
with strongly divergent age specific trends in colorec-
tal cancer mortality, we were unable to determine to 
what extent those variations were due to changes in 
the ICD code over the study period. Given these 
changes in coding practices, we opted for an inclusive 
approach in defining the anatomical location of col-
orectal cancer, by taking into account deaths due to 
cancers of the anus and anal canal in our analysis. 
These additional cancer sites represent only about 1% 
of all cancers of the large bowel. Potential misclassifi-
cations would therefore have a very limited effect on 
our results. 
Conclusions
Overall, since 1970, colorectal cancer mortality has been 
falling in most European countries. Largest reductions 
have been observed in western and northern Europe as 
a result of the combined influence of better public 
awareness of the disease, reduced prevalence in risk 
factors such as smoking and alcohol drinking, greater 
participation to screening, and improved treatment and 
patient management protocols. However, in southern, 
central, and eastern Europe—where mortality rates 
have either risen or modestly decreased—there are clear 
opportunities for improvement through primary and 
secondary prevention and better access to specialised 
care. Effective strategies already in place in several 
European countries, which have achieved large reduc-
tions in colorectal cancer mortality since 1970, repre-
sent valuable models for the design and implementation 
of such public health policies. 
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